Neuralign

Neuralign is a Toronto-based neurotechnology company operating at the intersection of neurodiagnostics and digital health, focused on identifying and treating reading and learning disabilities in children. The company has developed a proprietary digital platform that integrates standardized neuropsychological assessments with EEG-derived biomarkers to deliver objective, data-driven evaluations of cognitive and learning function. This diagnostic foundation is paired with neurofeedback and cognitive training tools designed to support therapeutic intervention following assessment. The platform is built for real-world deployment, with solutions compatible with the Lokomat rehabilitation system and structured for use across both school and clinical environments.

Neuralign has secured Series A funding of $8 million, signaling meaningful investor confidence in its approach to addressing a historically underserved segment of pediatric health. The company's go-to-market strategy targets institutional channels, embedding its tools directly within educational and clinical settings where learning disabilities are most commonly identified and managed. By combining diagnostic and therapeutic capabilities within a single platform, Neuralign is positioned to streamline the care pathway for children who might otherwise face lengthy referral processes and inconsistent assessments. This dual-function model also generates longitudinal data that can inform ongoing treatment decisions and outcome tracking at scale.

Neuralign represents an important development for the broader neurotech industry, demonstrating that EEG biomarkers and neuropsychological tools can be translated into accessible, scalable products for non-hospital settings. The company highlights a growing trend of neurodiagnostic innovation moving beyond research labs and into everyday clinical and educational practice. Its focus on pediatric learning disabilities addresses a condition affecting a substantial portion of the school-age population, many of whom lack access to timely and accurate diagnosis. As the industry seeks proof points for real-world neurotech utility, Neuralign's platform-based model offers a compelling example of how objective brain-based measurements can drive meaningful clinical and social outcomes.